APR Company Analysis 2026 — 92% of Revenue From Overseas, Record KRW 767.5bn Quarter

APR Company Analysis — A Company Where Triple-Digit YoY Growth Isn’t Unusual

I had been looking into the beauty-tech sector when I checked APR’s DART filings, and at first I thought I’d misread the numbers. Q2 2026 revenue came in at KRW 767.5 billion, up 134.2% year-over-year, and operating profit rose 134.5% to KRW 190.6 billion. Cumulative H1 revenue alone reached KRW 1,360.9 billion — already close to 89% of full-year 2025 revenue (KRW 1,527.3 billion). Given that 2023 revenue was KRW 523.8 billion, the company has nearly tripled its revenue in three years, and 2026 alone looks set to blow past all of last year’s results.

This is a beauty-tech company that makes both cosmetics — under brands including Medicube, AprilSkin, and other in-house labels — and home beauty devices under its AGE-R brand, best known for its Booster series. It listed on the KOSPI in February 2024, and founder Byung-hoon Kim is the largest shareholder, holding a 31.35% stake (34.16% including related parties). There are three questions I wanted to answer in this piece. First, what’s really behind revenue nearly tripling in three years? Second, how is the company maintaining — and even improving — an operating margin in the mid-20% range through this kind of explosive growth? Third, is 92% of revenue now coming from overseas a sustainable growth story, or does it carry real channel- and region-concentration risk? This analysis is based on APR’s 2026 semi-annual report and its 2023–2025 annual business reports filed with DART.

---

APR Company Overview — Key Data at a Glance

---

APR Business Structure — Beauty Tech Built on Devices, Cosmetics, and D2C

APR runs an unusual combination for a beauty company: it makes both cosmetics and home beauty devices under the same roof. Its cosmetics portfolio spans multiple brands including Medicube and AprilSkin, while its device business centers on the Booster series under its AGE-R brand. As of 2024, cosmetics and beauty products made up about 47% of segment revenue and home beauty devices about 43% — the two pillars are roughly balanced. Because the company sells largely through its own D2C (direct-to-consumer) commerce infrastructure rather than third-party retail, it captures distribution margin itself — a structure where profitability tends to improve, not erode, as the top line scales.

What stood out most in the Q2 2026 results was overseas revenue. It grew 178% year-over-year to top KRW 700 billion, accounting for 92% of total revenue. In the US, the company signed a deal with major off-price retail chain TJX to begin a physical retail push, while its new AGE-R device, the “Booster Pro X2,” rolled out across Amazon and TikTok Shop in North America and Europe. During Amazon Prime Day, 11 Medicube products ranked among the top performers in the beauty category. The picture that emerges is of a company moving well beyond the domestic Korean cosmetics market to scale up as a genuinely global D2C beauty-tech player.

---

APR 3-Year Financial Trend — Revenue Nearly Triples, Operating Margin Holds in the Mid-20s

What’s most striking in this table is that 2025 operating profit grew 197.9% year-over-year — nearly tripling. Just as notable is that the operating margin, which had dipped to 17.0% in 2024, rebounded to 23.9% in 2025 and 25.2% in H1 2026. Normally, revenue growing this fast comes at the cost of margin, squeezed by marketing and logistics spend. Here it’s happening in reverse. That reads as economies of scale flowing straight through to margin thanks to the D2C-centered distribution model. That said, the debt ratio jumping from 45.9% to 74.7% in 2024 and staying in the 70s since deserves a closer look, alongside the working-capital dynamics covered in the balance-sheet section below.

---

APR In-Depth Balance Sheet Analysis — Inventory More Than Doubled in Half a Year

The most eye-catching number on the balance sheet is inventory. It grew from KRW 165.46 billion at the end of 2025 to KRW 369.88 billion by mid-2026 — up 123.6% in just six months. Trade receivables rose 110.3% over the same period, both close to the pace of revenue growth (129.2%). That looks like a natural consequence of expanding into US offline retail (via TJX) and multiple e-commerce channels at once — the business now needs to pre-position inventory across more countries and channels simultaneously. The risk is that if this pace outruns actual sell-through, inventory turnover deteriorates and the company faces the prospect of discount-driven clearance sales or inventory write-downs down the road. Operating cash flow falling 27.5% year-over-year isn’t unrelated to this build in inventory and receivables. That said, CAPEX rising 118.1% alongside it — funding logistics and production infrastructure — suggests this inventory build may be less a simple pileup and more a deliberate, forward-leaning investment in global expansion.

---

APR CAPEX & New Business — What Offline Retail and Medical Devices Could Add Next

APR has grown almost entirely through online and D2C channels so far, but it’s now accelerating into offline retail as well. The clearest example is its deal with major US off-price retailer TJX to begin a brick-and-mortar push. Alongside that, AGE-R’s new device, the “Booster Pro X2,” has rolled out sequentially across Amazon and TikTok Shop in the US and UK — expanding online and offline distribution in parallel across markets. The company has guided for 2026 revenue of KRW 2.1–2.5 trillion (up 40–62% year-over-year) and expects the operating margin to hold near 25%, roughly in line with last year.

On the new-business front, the company is exploring entry into the medical device market, aiming to build on the technology and brand strength it has accumulated in home beauty devices. Medical devices carry a materially different regulatory bar and clinical-data burden than beauty devices, so this move warrants a cautious read — but if executed successfully, it would let the company expand into a market with higher barriers to entry, and likely higher margins, than home beauty devices alone. CAPEX growth backs up this expansion story: H1 2026 CAPEX alone reached KRW 16.79 billion, more than double the prior-year period, funding the logistics and production infrastructure this strategy depends on.

---

APR — Why Operating Profit Nearly Tripled in a Single Year

✅ 3 Investment Highlights

① Record Quarterly Revenue of KRW 767.5bn, 92% From Overseas
The company is scaling into a genuinely global D2C beauty-tech player, with Q2 overseas revenue up 178% year-over-year.

② Hypergrowth and Improving Margins at the Same Time
Revenue has nearly tripled in three years while the operating margin has climbed into the mid-20% range — growth and profitability improving together.

③ Offline Expansion Plus a New Device Diversify Growth Drivers
The TJX offline push in the US and the global rollout of the “Booster Pro X2” extend the company’s reach across online and offline channels alike, while a possible move into medical devices is under review.

⚠️ 3 Risks

① Inventory Surged 123.6% in Half a Year
Inventory growth outpacing revenue growth raises the risk of discount-driven clearance sales or inventory write-downs down the line.

② Regional and Currency Risk From Overseas Concentration
With overseas revenue now at 92% of the total, a slowdown in consumer spending in any single market, or currency swings, would have an outsized impact on results.

③ A Valuation That Already Prices in High Growth
Both results and the share price have moved sharply in a short period, already reflecting substantial growth expectations — if growth shows signs of slowing, the correction could be significant.

---

My Investment Judgment After Analyzing APR

What struck me most after digging into this company is that growth speed and profitability are improving together. Usually, growing the top line this fast comes at the expense of margin — here, thanks to the D2C structure, the operating margin is actually improving instead. That said, inventory surging 123.6% in half a year and operating cash flow declining are things I’ll want to see resolved in the next couple of quarters — whether this growth is genuinely sustainable, or whether the company has simply built up a temporary inventory cushion, is a question the next few quarters of results should answer.

My judgment is to increase my position (buying in tranches), while staying mindful of valuation. There are two key reasons behind that. First, overseas revenue surging 178% to reach 92% of the total doesn’t look like a one-off event — it looks like the structural result of expanding offline (TJX) and online (Amazon, TikTok Shop) channels at the same time. Second, the fact that the operating margin is improving even as revenue explodes shows the D2C business model’s leverage is genuinely working. That said, the inventory surge and an already growth-priced valuation are variables I’ll keep watching.

Here are the triggers that would change my judgment: ① confirmation within the next one or two quarters that the inventory buildup is being sold through normally and turnover is stabilizing (a positive signal), and ② a clear slowdown in overseas revenue growth or the emergence of inventory write-downs (a negative signal). If the latter signal becomes clear, I will stop adding to my position and move to a wait-and-see stance.

---

⚠️ Investment Disclaimer

This article is an individual investor’s analysis based on DART electronic disclosure filings and does not constitute investment advice.
All investment decisions must be made based on your own judgment and at your own responsibility.
Investing in stocks carries the risk of loss of principal.

---

References

• DART Electronic Disclosure System: https://dart.fss.or.kr
• APR official website: https://www.apr-in.com
• APR posts another record quarter, H1 revenue alone reaches KRW 1.36T (Financial News): https://www.fnnews.com/news/202608051015092608
• APR posts record quarter led by North America and Europe, overseas revenue share hits 92% (Newspim): https://www.newspim.com/news/view/20260805000268
• Basis of analysis: DART 2026 semi-annual report + 2023–2025 annual business reports (consolidated financial statements)